India’s NPPA slashes essential drug prices by up to 50%

pharmafile | January 26, 2017 | News story | Sales and Marketing India, nppa, pricing 

India’s governmental regulatory agency, the National Pharmaceutical Pricing Authority (NPPA), has addressed the pricing of 33 medicines including antibiotics and treatments for HIV, cancer and bacterial infections, slashing overall prices by 30-50% in a bid to improve access to commonly used drugs for damaging diseases.

Among the 33 controlled drugs, all listed on the revised National List of Essential Medicines 2015, 11 had their pricing capped, while the remaining 22 which were already subject to price caps have had their prices further reduced.

“NPPA has fixed/revised ceiling prices of 33 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order (DPCO), 2017 in related notification /order dated 24.01.2017,” the body said in a statement. “Manufacturers not complying with the ceiling price and notes specified herein above shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.”

The range of price controlled drugs now stands at 875, up from 684 since December last year; 627 drugs have had their prices capped by the NPPA since April 2015.

Other drugs affected by the NPPA’s actions include treatments for arthritis, psoriasis, ulcerative colitis and tuberculosis.

Matt Fellows

Related Content

Travellers with Indian-made AZ jab may face European ban

Up to 5 million Britons planning to travel to Europe may face a travel ban …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Bharat Biotech jab shows 100% efficacy against severe COVID-19

Indian biopharma company, Bharat Biotech, has reported interim analysis results from the Phase III trial …

Latest content